<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ressler HW</submitter><funding>National Institute of Neurological Disorders and Stroke</funding><funding>Tau Consortium</funding><funding>NIA NIH HHS</funding><funding>CurePSP</funding><funding>Stuart Katz</funding><funding>NINDS NIH HHS</funding><funding>Jane Martin</funding><funding>National Institute on Aging</funding><pagination>135</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11330133</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>12(1)</volume><pubmed_abstract>Progressive supranuclear palsy (PSP) is a neurodegenerative movement and cognitive disorder characterized by abnormal accumulation of the microtubule-associated protein tau in the brain. Biochemically, inclusions in PSP are enriched for tau proteoforms with four microtubule-binding domain repeats (4R), an isoform that arises from alternative tau pre-mRNA splicing. While preferential aggregation and reduced degradation of 4R tau protein is thought to play a role in inclusion formation and toxicity, an alternative hypothesis is that altered expression of tau mRNA isoforms plays a causal role. This stems from the observation that PSP is associated with common variation in the tau gene (MAPT) at the 17q21.31 locus which contains low copy number repeats flanking a large recurrent genomic invers</pubmed_abstract><journal>Acta neuropathologica communications</journal><pubmed_title>MAPT haplotype-associated transcriptomic changes in progressive supranuclear palsy.</pubmed_title><pmcid>PMC11330133</pmcid><funding_grant_id>U54NS115266</funding_grant_id><funding_grant_id>R01 NS086736</funding_grant_id><funding_grant_id>P30 AG066514</funding_grant_id><funding_grant_id>K01AG070326</funding_grant_id><funding_grant_id>R01 AG054008</funding_grant_id><funding_grant_id>T35 AG067578</funding_grant_id><funding_grant_id>U19 AG074879</funding_grant_id><funding_grant_id>685–2023-06</funding_grant_id><funding_grant_id>RF1NS095252</funding_grant_id><funding_grant_id>R01AG054008</funding_grant_id><funding_grant_id>U54 NS123743</funding_grant_id><funding_grant_id>R01NS086736</funding_grant_id><funding_grant_id>P30AG066514</funding_grant_id><funding_grant_id>T35AG067578</funding_grant_id><funding_grant_id>U54 NS115266</funding_grant_id><funding_grant_id>R01 AG062348</funding_grant_id><funding_grant_id>RF1 NS095252</funding_grant_id><funding_grant_id>R01AG062348</funding_grant_id><funding_grant_id>U54NS123743</funding_grant_id><funding_grant_id>685-2023-06</funding_grant_id><funding_grant_id>K01 AG070326</funding_grant_id><pubmed_authors>Dickson DW</pubmed_authors><pubmed_authors>Ressler HW</pubmed_authors><pubmed_authors>Babrowicz B</pubmed_authors><pubmed_authors>Kandoi S</pubmed_authors><pubmed_authors>Vialle RA</pubmed_authors><pubmed_authors>Crary JF</pubmed_authors><pubmed_authors>Farrell K</pubmed_authors><pubmed_authors>Humphrey J</pubmed_authors><pubmed_authors>Raj T</pubmed_authors><pubmed_authors>Ertekin-Taner N</pubmed_authors></additional><is_claimable>false</is_claimable><name>MAPT haplotype-associated transcriptomic changes in progressive supranuclear palsy.</name><description>Progressive supranuclear palsy (PSP) is a neurodegenerative movement and cognitive disorder characterized by abnormal accumulation of the microtubule-associated protein tau in the brain. Biochemically, inclusions in PSP are enriched for tau proteoforms with four microtubule-binding domain repeats (4R), an isoform that arises from alternative tau pre-mRNA splicing. While preferential aggregation and reduced degradation of 4R tau protein is thought to play a role in inclusion formation and toxicity, an alternative hypothesis is that altered expression of tau mRNA isoforms plays a causal role. This stems from the observation that PSP is associated with common variation in the tau gene (MAPT) at the 17q21.31 locus which contains low copy number repeats flanking a large recurrent genomic invers</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Aug</publication><modification>2026-06-02T04:45:40.666Z</modification><creation>2025-04-04T08:22:41.414Z</creation></dates><accession>S-EPMC11330133</accession><cross_references><pubmed>39154163</pubmed><doi>10.1186/s40478-024-01839-3</doi></cross_references></HashMap>